

AGE Reader Publication list

AGE Reader Key Publications

- **Skin autofluorescence predicts incident type 2 diabetes, cardiovascular disease and mortality in the general population.** van Waateringe R et al. *Diabetologia*. 2019 Feb;62(2):269-280 Epub
- **Skin Autofluorescence-Indicated Advanced Glycation End Products as Predictors of Cardiovascular and All-Cause Mortality in High-Risk Subjects: A Systematic Review and Meta-analysis.** Caverro-Redondo I. et al. *J Am Heart Assoc*. 2018 Sep 18;7(18)
- **Skin autofluorescence provides additional information to the UK Prospective Diabetes Study (UKPDS) risk score for the estimation of cardiovascular prognosis in type 2 diabetes mellitus.** Lutgers H. et al, *Diabetologia*, 2009; 52(5): 789-797
- **Skin autofluorescence and risk of micro- and macrovascular complications in patients with Type 2 diabetes mellitus-a multi-centre study.** Noordzij M.J. et al. *Diabet Med*. 2012 Dec;29(12):1556-61.
- **Skin Autofluorescence and the Association with Renal and Cardiovascular Risk Factors in Chronic Kidney Disease Stage 3.** McIntyre N. et al. *Clin J Am Soc Nephrol*. 2011 Sep 1. Epub
- **Skin Autofluorescence: A tool to identify type 2 diabetic patients at risk for developing microvascular disease.** Gerrits E. et al. *Diabetes Care*. 2008; 31: 517-521
- **Messung der Autofluoreszenz der Haut.** Stirban A. and Heinemann L. *Diabetes Stoffw Herz*. 2013; 22
- **Skin Autofluorescence Is Associated With 5-Year Mortality and Cardiovascular Events in Patients With Peripheral Artery Disease.** de Vos LC. et al. *Arterioscler Thromb Vasc Biol*. 2014 Feb 13.
- **Simple non-invasive assessment of advanced glycation endproducts accumulation.** Meerwaldt R et al, *Diabetologia*, 2004; 47:1324-1330

AGE Reader in diabetes

1. **Skin Autofluorescence Is Associated with Diabetic Peripheral Neuropathy in Chinese Patients with Type 2 Diabetes** Wan L. *Genet Test Mol Biomarkers* 2019 Jun 23(6): 387
2. **AGE and diabetic vascular complications in type 2 diabetes** Osawa S. *J of Diabetes and its Complications* 2018 Sept: 839-844
3. **Gradual increase in advanced glycation end-products from no diabetes to early and regular gestational diabetes: A case-control study.** Cosson E. *Diabetes and Metabolism* 2018 Febr 2 Epub
4. **Skin Autofluorescence is a Noninvasive Surrogate Marker for Diabetic Microvascular Complications and Carotid Intima-Media Thickness in Japanese Patients with Type 2 Diabetes: A Cross-sectional Study.** Yoshioka K. *Diabetes Ther*. 2017 Nov 24. doi: 10.1007/s13300-017-0339-3.

5. **Fokkens B.T. et al. Skin autofluorescence improves the Finnish Diabetes Risk Score in the detection of diabetes in a large population-based cohort: The Lifelines Cohort Study.**
Fokkens B. et al. *Diabetes Metab.* 2017 Oct 30. pii: S1262-3636(17)30513-X. doi: 10.1016/j.diabet.2017.09.002.
6. **Ethnicity and skin autofluorescence-based risk-engines for cardiovascular disease and diabetes mellitus.** Ahmad M.S. et al. *PLoS One.* 2017 Sep 20;12(9):e0185175.
7. **Progression of skin autofluorescence of AGEs over 4 years in patients with type 1 diabetes.**
Rajaobelina K et al. *Diabetes Metab Res Rev.* 2017 Jul 18. doi: 10.1002/dmrr.2917.
8. **The relationship between circulating irisin levels and tissues AGE accumulation in type 2 diabetes patients.**
Li Z. et al. *Biosci Rep.* 2017 Apr 13. doi: 10.1042/BSR20170213.
9. **Vitreous advanced glycation endproducts and α -dicarbonyls in retinal detachment patients with type 2 diabetes mellitus and non-diabetic controls.**
Fokkens B.T. et al. *PLoS One.* 2017 Mar 6;12(3):e0173379. doi: 10.1371/journal.pone.0173379.
10. **Skin autofluorescence, renal insufficiency and retinopathy in patients with type 2 diabetes.**
Bentata R. et al. *J Diabetes Complications.* 2016 Oct 30. [Epub ahead of print]
11. **Association between small fiber neuropathy and higher skin accumulation of advanced glycation end products in patients with type 1 diabetes.**
Araszkiewicz A, et al. *Pol Arch Med Wewn.* 2016 Nov 22;126(11):847-853.
12. **Risk factors for autonomic and somatic nerve dysfunction in different stages of glucose tolerance.**
Dimova R, et al. *J Diabetes Complications.* 2016 Nov 6. [Epub ahead of print]
13. **Skin autofluorescence (a marker for advanced glycation end products) and erectile dysfunction in diabetes.**
Kouidrat Y. et al. *J Diabetes Complications.* 2016 Oct 29. pii: S1056-8727(16)30351-8. [Epub ahead of print]
14. **Skin autofluorescence is increased in young people with type 1 diabetes exposed to secondhand smoking.**
Vollenbrock CE. et al. *J Diabetes.* 2016 Oct 27. (Epub).
15. **Higher skin autofluorescence in young people with Type 1 diabetes and microvascular complications.**
Cho YH. et al. *Diabet Med.* 2016 Oct 22. (Epub)
16. **Advanced glycation end products is a risk for muscle weakness in Japanese patients with type 1 diabetes.** Mori H. et al. *J Diabetes Investig.* 2016 Oct 11. (Epub) (FULL TEXT available)
17. **Skin Autofluorescence is Associated with Early-stage Atherosclerosis in Patients with Type 1 Diabetes.** Osawa S et al. *J Atheroscler Thromb.* 2016 Sep 2.
18. **Skin autofluorescence predicts cardio-renal outcome in type 1 diabetes: a longitudinal study.**
Vélayoudom-Céphise FL et al. *Cardiovasc Diabetol.* 2016 Sep 1;15(1):127.
19. **Skin Autofluorescence and Pentosidine Are Associated With Aortic Stiffening: The Maastricht Study.**
van Eupen MG et al. *Hypertension.* 2016 Oct;68(4):956-63.
20. **Skin fluorescence as a clinical tool for non-invasive assessment of advanced glycation and long-term complications of diabetes.**
Fokkens BT, Smit AJ. *Glycoconj J.* 2016 Aug;33(4):527-35.
21. **ADVANCED GLYCATION END PRODUCT (AGE) ACCUMULATION IN THE SKIN IS ASSOCIATED WITH DEPRESSION: THE MAASTRICHT STUDY.**
van Dooren FE et al. *Depress Anxiety.* 2016 Jun 6. (Epub)
22. **Skin autofluorescence and peripheral neuropathy four years later in type 1 diabetes.**
Rajaobelina K. et al. *Diabetes Metab Res Rev.* 2016 May 27. Epub
23. **The relationship between advanced glycation endproducts and ocular circulation in type 2 diabetes.** Hashimoto K. et al. *J Diabetes Complications* 2016 May 4. Epub.

24. **Advanced Glycation Endproducts and Bone Material Strength in Type 2 Diabetes.**
Furst J.R. et al. J Clin Endocrinol Metab. 2016 Apr 26. Epub.
25. **Association of Advanced Glycation End Products with coronary Artery Calcification in Japanese Subjects with Type 2 Diabetes as Assessed by Skin Autofluorescence.**
Hangai M. et al. J Atheroscler Thromb. 2016 Mar 10.
26. **Non-invasive Measurement of Skin Autofluorescence as a Beneficial Surrogate Marker for Atherosclerosis in Patients with Type 2 Diabetes.**
Temma J. et al. J Med Invest. 2015;62(3-4):126-9.
27. **Advanced glycation end products, measured in skin, vs. HbA1c in children with type 1 diabetes mellitus.** Banser A. et al. Pediatr Diabetes. 2015 Sep 2.
28. **Relationship between skin auto fluorescence and conventional glycemic markers in patients with diabetes.**
Mácsai E. et al. Orv Hetil. 2015 Aug 16;156(33):1341-7.
29. **In diabetic Charcot neuroarthropathy impaired microvascular function is related to long lasting metabolic control and low grade inflammatory process.**
Araszkievicz A. et al. Microvasc Res. 2015 Aug 1;101:143-147.
30. **Vitamin D status is associated with skin autofluorescence in patients with type 2 diabetes mellitus: a preliminary report.**
Krul-Poel Y.H. et al. Cardiovasc Diabetol. 2015 Jul 16;14:89.
31. **Is skin autofluorescence a marker of metabolic memory in pregnant women with diabetes?**
Maury E. et al. Diabet Med. 2015 May 16.
32. **The Association Between Skin Autofluorescence and Vascular Complications in Chinese Patients With Diabetic Foot Ulcer: An Observational Study Done in Shanghai.**
Liu C. et al. Int J Low Extrem Wounds. 2015. (Epub)
33. **Autofluorescence of Skin Advanced Glycation End Products: Marker of Metabolic Memory in Elderly Population.**
Rajaobelina K. et al. J Gerontol A Biol Sci Med Sci. 2015 Jan 14 (Epub)
34. **Skin autofluorescence is associated with carotid intima-media thickness, diabetic microangiopathy, and long-lasting metabolic control in type 1 diabetic patients. Results from Poznan Prospective Study.** Araszkievicz A. et al. Microvasc Res. 2015 Jan 10 (Epub)
35. **Skin collagen advanced glycation endproducts (AGEs) and the long-term progression of sub-clinical cardiovascular disease in type 1 diabetes,** Monnier et al. Cardiovasc Diabetol 2015;14:118
36. **Association of advanced glycation end products and chronic kidney disease with macroangiopathy in type 2 diabetes.**
Rigalleau V. et al. J Diabetes Complications. 2014 Oct 30. Epub
37. **Advanced glycation end products (AGEs) and the soluble receptor for AGE (sRAGE) in patients with type 1 diabetes and coeliac disease.**
Bakker S.F. et al. Nutr Metab Cardiovasc Dis. 2014 Nov 1.Epub
38. **Associations of advanced glycation endproducts with cognitive functions in individuals with and without type 2 diabetes.**
Spauwen P.J. et al. J Clin Endocrinol Metab. 2014 Dec 2
39. **Relationship of Skin Autofluorescence to Severity of Retinopathy in Type 2 Diabetes.**
Yasuda M. et al. Curr Eye Res. 2014 May 28:1-8.
40. **Type 2 diabetes mellitus, skin autofluorescence and brain atrophy.**
Moran C. et al. Diabetes. 2014 Jul 22.

41. **AGEs and chronic subclinical inflammation in diabetes: disorders of immune system.**
Hu H. et al. Diabetes Metab Res Rev. 2014 May 20. Epub
42. **Correlation between diabetic makuls severity and elevated skin autofluorescence as a marker of advanced glycation end-product accumulation in type 2 diabetic patients.**
Hirano T. et al. J Diabetes Complications. 2014 Mar 10. Epub
43. **Advanced glycation end products are associated with arterial stiffness in type 1 diabetes.**
Llauradó G. et al. J Endocrinol. 2014 Jun;221(3):405-13.
44. **Messung der Autofluoreszenz der Haut.**
Stirban A. and Heinemann L. Diabetes Stoffw Herz. 2013; 22 (full text available)
45. **Skin autofluorescence relates to soluble receptor for advanced glycation end-products and albuminuria in diabetes mellitus.**
Skrha J Jr. et al. J Diabetes Res. Epub 2013 Mar 10.
46. **Skin autofluorescence based decision tree in detection of impaired glucose tolerance and diabetes.**
Smit AJ. et al. PLoS One. 2013 Jun 4;8(6):e65592.
47. **Potential inhibitory effects of L-carnitine supplementation on tissue advanced glycation end products in patients with hemodialysis.**
Fukami K. Rejuvenation Res. 2013 Aug 4. [Epub ahead of print]
48. **Skin autofluorescence relates to soluble receptor for advanced glycation end-products and albuminuria in diabetes mellitus.**
Skrha J Jr. et al. J Diabetes Res. 2013;2013:650694.
49. **Skin autofluorescence is associated with past glycaemic control and complications in type 1 diabetes mellitus.**
Genevieve M. et al. Diabetes Metab. 2013 May 2. [Epub ahead of print]
50. **Advanced Glycation End Products Assessed by Skin Autofluorescence-A New Marker of Diabetic Foot Ulceration.**
Vouillarmet J. et al. Diabetes Technol Ther. 2013 Apr 30. [Epub ahead of print]
51. **Study design of DIACORE (DIAbetes COHoRtE) - a cohort study of patients with diabetes mellitus type 2.**
Dörhöfer L, BMC Med Genet. 2013 Feb 14;14:25.
52. **Verification of Skin Autofluorescence Values by Mass Spectrometry in Adolescents with Type 1 Diabetes: Brief Report.**
Mácsai E. et al. Diabetes Technol Ther. 2013 Jan 23.
53. **Advanced glycation end products in infant formulas do not contribute to insulin resistance associated with their consumption.**
Klenovics KS. et al. PLoS One. 2013;8(1):e53056.
54. **Advanced Glycation End Products, Measured as Skin Autofluorescence, During Normal Pregnancy and Pregnancy Complicated by Diabetes Mellitus.**
de Ranitz-Greven WL. et al. Diabetes Technol Ther. 2012 Oct 31. (Epub)
55. **Skin autofluorescence measurement in diabetological and nephrological clinical practice.**
Mácsai E. et al. Orv Hetil. 2012 Oct 21;153(42):1651-7.
56. **Skin autofluorescence and risk of micro- and macrovascular complications in patients with Type 2 diabetes mellitus-a multi-centre study.**
Noordzij M.J. et al. Diabet Med. 2012 Aug 31. doi: 10.1111/dme.12005.
57. **Advanced glycation end products measured by skin autofluorescence in a population with central obesity.**
den Engelsen C. et al. Dermatoendocrinol. 2012 Jan 1;4(1):33-8.

58. **Elevated skin autofluorescence is strongly associated with foot ulcers in patients with diabetes: a cross-sectional, observational study of Chinese subjects.**
Hu H. et al. J Zhejiang Univ Sci B. 2012 May;13(5):372-7.
59. **Advanced Glycation Endproducts and Diabetic Cardiovascular Disease.**
Prasad A. et al. Cardiol Rev. 2012 Feb 6. Epub
60. **Non-invasive measures of tissue autofluorescence are increased in Type 1 diabetes complications and correlate with a non-invasive measure of vascular dysfunction.**
Januszewski A.S. et al. Diabet Med. 2011 Dec 28. doi: 10.1111/j.1464-5491.2011.03562.x.
61. **Skin autofluorescence is associated with severity of vascular complications in Japanese patients with Type 2 diabetes.** Tanaka K. et al. Diabet Med. 2011 Sep 14. Epub
62. **Skin autofluorescence is inversely related to HDL anti-oxidative capacity in type 2 diabetes mellitus.**
Mulder D. et al. Atherosclerosis. 2011 May, Epub
63. **Advanced Glycation End Products, Measured as Skin Autofluorescence, at Diagnosis in Gestational Diabetes Mellitus Compared with Normal Pregnancy.**
de Ranitz-Greven WL et al. Diabetes Technol Ther. 2011 Aug 29. Epub
64. **Increased accumulation of skin advanced glycation end products is associated with microvascular complications in type 1 diabetes.**
Araszkievicz A. et al. Diabetes Technol Ther. 2011 Aug;13(8):837-42.
65. **Assessment of skin autofluorescence as a marker of advanced glycation end product accumulation in type 1 diabetes.**
Samborski P. et al. Pol Arch Med Wewn. 2011 Mar;121(3):67-72.
66. **Advanced glycation end products, measured as skin autofluorescence and diabetes complications: a systematic review.**
Bos D.C. et al. Diabetes Technol Ther. 2011 Jul;13(7):773-9.
67. **Tissue advanced glycation end products are associated with diastolic function and aerobic exercise capacity in diabetic heart failure patients.**
Willemsen S. et al. Eur J. Heart Fail 2010. doi:10.1093/eurjhf/hfq168
68. **Skin autofluorescence and glycemic variability.**
Noordzij M. et al. Diabetes Technol Ther. 2010; 12(7): 581-585
69. **Advanced glycation end products assessed by skin autofluorescence in type 1 diabetics are associated with nephropathy, but not retinopathy.**
Chabroux S. et al: Diabetes Metab, 2010 Apr;36(2):152-7.
70. **Skin autofluorescence provides additional information to the UK Prospective Diabetes Study (UKPDS) risk score for the estimation of cardiovascular prognosis in type 2 diabetes mellitus**
Lutgers H. et al: Diabetologia, 2009; 52(5): 789-797
71. **Skin Autofluorescence: A tool to identify type 2 diabetic patients at risk for developing microvascular disease.**
Gerrits E. et al. Diabetes Care. 2008; 31: 517-521
72. **Skin autofluorescence is a strong predictor of cardiac mortality in diabetes**
Meerwaldt R, et al. Diabetes Care 2007, 30: 107-112
73. **Skin autofluorescence in type 2 diabetes: Beyond blood glucose**
Monami M. et al. Diabetes Research & Clinical Practice July 2007. epub
74. **Non-invasive AGE-measurements by skin autofluorescence in patients with Type 2 Diabetes Mellitus. Tool for risk-assessment of diabetes complications?**
Lutgers H, et al. Diabetes Care. 2006 Dec;29(12):2654-9

- 75. Increased accumulation of skin advanced glycation end-products precedes and correlates with clinical manifestation of diabetic neuropathy**
Meerwaldt R, et al. Diabetologia. 2005;48:1637-44.
- 76. The clinical relevance of advanced glycation endproducts (AGE) and recent developments in pharmaceuticals to reduce AGE accumulation.**
Smit AJ, Lutgers HL. Curr Med Chem. 2004 Oct;11(20):2767-84.
- 77. Therapeutic options to reduce advanced glycation end products in patients with diabetes mellitus: A review. P.**
Judd and H. Sourij 2018 Diab. res. clin. prac. 148 (2019) 54–63

AGE Reader in cardiovascular disease

- 78. Skin accumulation of advanced glycation end products is increased in patients with an abdominal aortic aneurysm.**
Boersema J. et al. J Vasc Surg. 2017 Jun 24. pii: S0741-5214(17)31144-8.
- 79. Impact of Hemorheology Assessed by the Microchannel Method on Pulsatility Index of the Common Carotid Artery in Patients With Type 2 Diabetes Mellitus.**
Hitsumoto T. et al. J Clin Med Res. 2017 Jul;9(7):579-585.
- 80. Diverging effects of diabetes mellitus in patients with peripheral artery disease and abdominal aortic aneurysm and the role of advanced glycation end-products: ARTERY study - protocol for a multicentre cross-sectional study.**
de Vos L.C. et al. BMJ Open. 2017 Apr 11;7(4):e012584. doi: 10.1136/bmjopen-2016-012584.
- 81. A Comparative Study on Skin and Plasma Advanced Glycation End Products and Their Associations with Arterial Stiffness.**
Liu C.Y. et al. Pulse (Basel). 2017 Jan;4(4):208-218.
- 82. Association of Skin Autofluorescence Levels With Kidney Function Decline in Patients With Peripheral Artery Disease.**
Schutte E et al. Arterioscler Thromb Vasc Biol. 2016 Aug;36(8):1709-14.
- 83. The Relationship Between Level of End-Products of Tissue Glycation and Pulse Wave Velocity in Non-diabetic Patients With Cardiovascular Disease.**
Ageev F.T. et al. Kardiologiia. 2015;55(6):63-7.
- 84. Skin autofluorescence as a measure of advanced glycation end products deposition predicts 5-year amputation in patients with peripheral artery disease.**
de Vos LC. et al. Arterioscler Thromb Vasc Biol. 2015 Jun;35(6):1532-7.
- 85. Evaluation of tissue accumulation levels of advanced glycation end products by skin autofluorescence: A novel marker of vascular complications in high-risk patients for cardiovascular disease.**
Yamagishi S.I. et al. Int J Cardiol. 2015 Mar (Epub)
- 86. Skin autofluorescence, 5-year mortality, and cardiovascular events in peripheral arterial disease: all that glitters is surely not gold.**
Schmidt AM. Arterioscler Thromb Vasc Biol. 2014 Apr;34(4):697-9.
- 87. Skin Autofluorescence Is Associated With 5-Year Mortality and Cardiovascular Events in Patients With Peripheral Artery Disease.**
de Vos LC. et al. Arterioscler Thromb Vasc Biol. 2014 Feb 13.

- 88. Skin Autofluorescence, a Non-Invasive Marker for AGE Accumulation, Is Associated with the Degree of Atherosclerosis.**
den Dekker MA. et al. PLoS One. 2013 Dec 23;8(12):e83084.
- 89. Skin autofluorescence as proxy of tissue AGE accumulation is dissociated from SCORE cardiovascular risk score, and remains so after 3 years.**
Tiessen AH. et al. Clin Chem Lab Med. 2013 Apr 2:1-7.
- 90. Skin Autofluorescence as a Measure of Advanced Glycation End Product Deposition Is Elevated in Peripheral Artery Disease.**
de Vos L.C. et al. Arterioscler Thromb Vasc Biol. 2012 Nov 8. (Epub)
- 91. Relationship between tissue glycation measured by autofluorescence and pulse wave velocity in young and elderly non-diabetic populations.**
Watfa G. et al. Diabetes Metab. 2012 Jun 13.
- 92. Advanced glycation end product associated skin autofluorescence: A mirror of vascular function?**
Hofmann B. et al. Exp Gerontol. 2012 May 12.
- 93. Effects of alagebrium, an advanced glycation endproduct breaker, on exercise tolerance and cardiac function in patients with chronic heart failure.**
Hartog J.W. et al. BENEFICIAL investigators. Eur J Heart Fail. 2011 Aug;13(8):899-908.
- 94. Skin autofluorescence is increased in patients with carotid artery stenosis and peripheral artery disease.**
Noordzij MJ. Int J Cardiovasc Imaging. 2011 Feb. Epub
- 95. Carotid artery intima media thickness associates with skin autofluorescence in non-diabetic subjects without clinically manifest cardiovascular disease.**
Lutgers H. et al. Eur J Clin Invest. 2010 ;40(9):812-7
- 96. Advanced glycation end-products, anti-hypertensive treatment and diastolic function in patients with hypertension and diastolic dysfunction.**
Hartog J. et al; Eur. Journal of Heart Failure, 2010 Apr;12(4):397-403
- 97. Advanced glycation end products in patients with cerebral infarction.**
Ohnuki Y. Intern Med. 2009;48(8):587-91.
- 98. Advanced Glycation End Products and their receptor RAGE in systemic autoimmune diseases - an inflammation propagating factor contributing to accelerated atherosclerosis.**
Nienhuis et al. Autoimmunity, 2009; 42(4): 302-304
- 99. Skin autofluorescence is elevated in acute myocardial infarction and is associated with the one-year incidence of major adverse cardiac events**
Mulder D. et al, Netherlands Heart Journal, Volume 17, Number 4, April 2009
- 100. Relation between food and drinking habits, and skin autofluorescence and intima media thickness in subjects at high cardiovascular risk**
Jochemsen M. et al: Journal of Food and Nutrition Research Vol. 48, 2009, No. 1, pp. 51–58
- 101. Advanced Glycation Endproducts (AGE) in chronic heart failure**
Smit A. et al. Annals of New York Academy of Science 2008; 1126:225-30
- 102. Clinical relevance of Advanced Glycation Endproducts for vascular surgery**
Meerwaldt R. et al. Eur J Vasc Endovasc Surg. 2008; 38,125-131
- 103. Skin autofluorescence is elevated in patients with stable coronary artery disease and is associated with serum levels of neopterin and the soluble receptor for advanced glycation end products.**
Mulder DJ. et al. Atherosclerosis. 2007;197:217-223

- 104. Clinical and prognostic value of Advanced Glycation End-products (AGEs) in chronic heart failure.**
Hartog J. et al Eur J Heart Failure 2007;9:1146-55
- 105. Skin Autofluorescence is an independent marker for Acute Myocardial Infarction**
Mulder DJ, et al. Circulation: 2005; 112:II-371.
- 106. Skin Autofluorescence-Indicated Advanced Glycation End Products as Predictors of Cardiovascular and All-Cause Mortality in High-Risk Subjects: A Systematic Review and Meta-analysis.** Cavero-Redondo I. et al. J Am Heart Assoc. 2018 Sep 18;7(18)
- 107. Skin autofluorescence is associated with inappropriate left ventricular mass and diastolic dysfunction in subjects at risk for cardiovascular disease.** Wang et al. Cardiovascular Diabetology 2017 16:15
- 108. Association between the tissue accumulation of advanced glycation end products and exercise capacity in cardiac rehabilitation patients.** Kunimoto et al. 2020 BMC Cardiovascular disorders (2020) 20:195
<https://doi.org/10.1186/s12872-020-01484-3>

AGE Reader in renal disease

- 109. The association of skin autofluorescence with cardiovascular events and all-cause mortality in persons with chronic kidney disease stage 3: A prospective cohort study.** Shardlow et al. 2020 PLoS Med 17(7): e1003163.
<https://doi.org/10.1371/journal.pmed.1003163>
- 110. Impact of a medium cut-off dialyzer on skin autofluorescence in haemodialysis patients.** Viramontes et al. 2020 poster EDTA
- 111. Skin autofluorescence and malnutrition as predictors of mortality in persons receiving dialysis: a prospective cohort study.** Viramontes Hörner et al. 2020 J Hum Nutr Diet. <https://doi.org/10.1111/jhn.12764>
- 112. Factors Associated With Change in Skin Autofluorescence, a Measure of Advanced Glycation End Products, in Persons Receiving Dialysis** Viramontes Hörner et al. 2020. Kidney Int Rep (2020) 5, 654–662;
<https://doi.org/10.1016/j.ekir.2020.02.003>
- 113. Skin autofluorescence is associated with rapid renal function decline in subjects at increased risk of coronary artery disease.** Wang C.C. et al. PLoS ONE 2019 May 22 14(5): e0217203.
- 114. Advanced glycation end-products (AGEs) accumulation in skin: relations with chronic kidney disease-mineral and bone disorder.**
França R.A. et al. J Bras Nefrol. 2017 Jul-Sep;39(3):253-260.
- 115. Skin autofluorescence in acute kidney injury.**
Lavielle A. et al. Crit Care. 2017 Feb 9;21(1):24.
- 116. Skin- and Plasmaautofluorescence in hemodialysis with glucose-free or glucose-containing dialysate.** Ramsauer B, et al. BMC Nephrol. 2017 Jan 5;18(1):5.
- 117. Comparing changes in plasma and skin autofluorescence in low-flux versus high-flux hemodialysis.**
Ramsauer B. et al. Int J Artif Organs. 2015 (Epub)
- 118. Skin Autofluorescence Is Associated with Endothelial Dysfunction in Uremic Subjects on Hemodialysis.** Wang CC. et al. PLoS One. 2016 Jan 25;11(1):e0147771.
- 119. Skin autofluorescence advanced glycosylation end products (AGEs) as an independent predictor of mortality in high flux haemodialysis and haemodialysis patients.**
Nongnuch A. et al. Nephrology (Carlton). 2015 May 25.

120. **The effect of vegetarian diet on skin autofluorescence measurements in haemodialysis patients.** Nongnuch A. et al. *Br J Nutr.* 2015 Mar 12;1-4. (Epub)
121. **Skin Autofluorescence Is a Predictor of Cardiovascular Disease in Chronic Kidney Disease Patients.** Furuya F. et al. *Ther Apher Dial.* 2014 Dec 29.
122. **Tissue advanced glycation end products (AGEs), measured by skin autofluorescence, predict mortality in peritoneal dialysis.** Siritopol D. et al. *Int Urol Nephrol.* 2014 Nov 26.
123. **Skin autofluorescence as a novel marker of vascular damage in children and adolescents with chronic kidney disease.** Makulska I. et al. *Pediatr Nephrol.* 2014 Nov 20.
124. **Skin autofluorescence associates with vascular calcification in chronic kidney disease.** Maku A.Y. et al. *Arterioscler Thromb Vasc Biol.* 2014 Aug;34(8):1784-90
125. **Skin Autofluorescence and All-Cause Mortality in Stage 3 CKD.** Fraser S.D. et al. *Clin J Am Soc Nephrol.* 2014 May 29. Epub
126. **Skin Autofluorescence Predicts Cardiovascular Mortality in Patients on Chronic Hemodialysis.** Kimura H. et al. *Ther Apher Dial.* 2014 Jan 24
127. **Skin autofluorescence is associated with the progression of chronic kidney disease: a prospective observational study.** Tanaka K. et al. *PLoS One.* 2013 Dec 12;8(12):e83799.
128. **Skin and Plasma Autofluorescence During Hemodialysis: A Pilot Study.** Graaff R. et al. *Artif Organs.* 2013 Oct 29.
129. **Tissue Advanced Glycation End Product Deposition after Kidney Transplantation.** Crowley LE et al. *Nephron Clin Pract.* 2013 Oct 15;124(1-2):54-59.
130. **Advanced glycation end-products and skin autofluorescence in end-stage renal disease: a review.** Arsov S. et al. *Clin Chem Lab Med.* 2013 Apr 4:1-10.
131. **Accumulation of tissue advanced glycation end products correlated with glucose exposure dose and associated with cardiovascular morbidity in patients on peritoneal dialysis.** Jiang J. et al. *Atherosclerosis.* 2012 Sep;224(1):187-94.
132. **Skin autofluorescence as a marker of cardiovascular risk in children with chronic kidney disease.** Siritopol I. et al. *Pediatr Nephrol.* 2012 Sep 15. (Epub)
133. **Factors influencing skin autofluorescence of patients with peritoneal dialysis.** Mácsai E. et al. *Acta Physiol Hung.* 2012 Jun;99(2):216-22.
134. **Decreased serum carnitine is independently correlated with increased tissue accumulation levels of advanced glycation end products in hemodialysis patients.** Adachi T. et al. *Nephrology (Carlton).* 2012 Jul 13. doi: 10.1111/j.1440-1797.2012.01642.x.
135. **Skin Autofluorescence: A Pronounced Marker of Mortality in Hemodialysis Patients.** Gerrits E. et al. *Nephron Extra.* 2012 Jan;2(1):184-191.
136. **Advanced oxidation protein products and advanced glycation end products in children and adolescents with chronic renal insufficiency.** Sebeková K. *J Ren Nutr.* 2012 Jan;22(1):143-8.
137. **Evaluation of advanced glycation end products accumulation, using skin autofluorescence, in CKD and dialysis patients.** Oleniuc M. et al. *Int Urol Nephrol.* 2011 Oct;44(5):1441-9.

- 138. Skin autofluorescence and the association with renal and cardiovascular risk factors in chronic kidney disease stage 3.**
McIntyre N.J. et al. Clin J Am Soc Nephrol. 2011 Oct;6(10):2356-63.
- 139. Tissue level of advanced glycation end products is an independent determinant of high-sensitivity C-reactive protein levels in haemodialysis patients.**
Nagano M. et al. Nephrology (Carlton). 2011 Mar;16(3):299-303
- 140. Skin autofluorescence as a measure of advanced glycation endproduct deposition: a novel risk marker in chronic kidney disease.**
Smit AJ. et al. Curr Opin Nephrol Hypertens, 2010; 19(6):527-33.
- 141. Skin autofluorescence is associated with renal function and cardiovascular diseases in pre-dialysis chronic kidney disease patients.**
Tanaka K. et al. Nephrol Dial Transplant. doi: 10.1093/ndt/gfq369
- 142. Advanced glycation end products, carotid atherosclerosis, and circulating endothelial progenitor cells in patients with end-stage renal disease.**
Ueno H et al. Metabolism, 2010, doi: 10.1016/j.metabol.2010.04.001
- 143. Tissue-Advanced Glycation End Product Concentration in Dialysis Patients**
McIntyre et al; CJASN, 2010; 5(1): 51-55
- 144. Does hepatitis C increase the accumulation of advanced glycation end products in haemodialysis patients?**
Arsov S. et al. Nephrol Dial Transplant 2009; 25(3): 885-891
- 145. Skin-Autofluorescence Is an Independent Predictor of Graft Loss in Renal Transplant Recipients**
Hartog J. et al, Transplantation • Volume 87, Number 7, April 15, 2009
- 146. Advanced Glycation End Products in Renal Failure: An Overview**
Noordzij M. et al, Journal of Renal Care 2008
- 147. AGEs, autofluorescence and renal failure** Gerrits E. et al. Nephrology Dialysis and Transplantation 2009; 24: 710-713
- 148. Skin autofluorescence, a marker for advanced glycation end product accumulation, is associated with arterial stiffness in patients with end-stage renal disease**
Ueno H. et al: Metabolism Clinical and Experimental 57 (2008) 1452–1457
- 149. Skin Autofluorescence, a measure of tissue advanced glycation endproducts (AGEs), is related to the diastolic function of dialysis patients**
Hartog J. et al. Journal of Cardiac Failure. 2008; 14(7): 596-602
- 150. Risk factors for chronic transplant dysfunction and cardiovascular disease are related to accumulation of advanced glycation end-products in renal transplant recipients**
Hartog JW, et al. Nephrol Dial Transpl 2006 Aug;21(8):2263-9
- 151. Skin autofluorescence, a measure of cumulative metabolic stress and advanced glycation endproducts, predicts mortality in hemodialysis patients**
Meerwaldt R, et al. J Am Soc Nephrol 2005;16:3687-93.
- 152. Skin autofluorescence, a noninvasive measure of advanced glycation end product accumulation, is a predictor of mortality in hemodialysis patients**
Meerwaldt R, et al. Ann N Y Acad Sci 2005;1043:911.
- 153. Accumulation of advanced glycation end products, measured as skin autofluorescence, in renal disease.**
Hartog JW. et al. Ann N Y Acad Sci. 2005 Jun;1043:299-307.

154. Advanced glycation endproducts in kidney transplant patients: a putative role in the development of chronic renal transplant dysfunction

Hartog J. et al. *Am J Kidn Dis* 2004; 43:966-975

AGE Reader in cardiac surgery

155. It's all in our skin—Skin autofluorescence—A promising outcome predictor in cardiac surgery: A single centre cohort study. Hofmann et al. 2020 *PLOS ONE* 15(6): e0234847 <https://doi.org/10.1371/journal.pone.0234847>

AGE Reader in other diseases

156. Autofluorescence of Skin Advanced Glycation End Products as a Risk Factor for Open Angle Glaucoma: The ALIENOR Study.

Schweitzer C. et al. *Invest Ophthalmol Vis Sci*. 2018 Jan 1;59(1):75-84.

157. Association Between Accumulation of Advanced Glycation End-Products and Hearing Impairment in Community-Dwelling Older People: A Cross-Sectional Sukagawa Study.

Niihata K. et al. *J Am Med Dir Assoc*. 2017 Nov 1. pii: S1525-8610(17)30520-0. doi: 0.1016/j.jamda.2017.09.008.

158. Accumulation of advanced glycation end products evaluated by skin autofluorescence and incident frailty in older adults from the Bordeaux Three-City cohort.

Pilleron S. et al. *PLoS One*. 2017 Oct 17;12(10):e0186087.

159. Skin autofluorescence, a non-invasive biomarker for advanced glycation end products, is associated with the metabolic syndrome and its individual components.

van Waateringe RP et al. *Diabetol Metab Syndr*. 2017 May 30;9:42.

160. Association between habitual dietary and lifestyle behaviours and skin autofluorescence (SAF), a marker of tissue accumulation of advanced glycation endproducts (AGEs), in healthy adults.

Kellow NJ et al. *Eur J Nutr*. 2017 Jun 27. doi: 10.1007/s00394-017-1495-y.

161. Advanced Glycation End Products in Recent-Onset Psychosis Indicate Early Onset of Cardiovascular Risk. Hagen JM et al. *J Clin Psychiatry*. 2017 Apr 25. doi: 10.4088/JCP.16m10972.

162. Advanced glycation end-products in morbid obesity and after bariatric surgery: When glycemic memory starts to fail.

Sánchez E. et al. *Endocrinol Diabetes Nutr*. 2017 Jan;64(1):4-10.

163. Advanced glycation end products as a biomarker for incisional hernia.

Harlaar JJ et al. *Hernia*. 2017 Apr 12. doi: 10.1007/s10029-017-1610-2. [Epub ahead of print]

164. Advanced glycation end-products (AGEs) and associations with cardio-metabolic, lifestyle, and dietary factors in a general population: the NQplus study.

Botros N. et al. *Diabetes Metab Res Rev*. 2017 Mar 1. doi: 10.1002/dmrr.2892.

165. Skin advanced glycation end-products evaluation in infants according to the type of feeding and mother's smoking habits.

Federico G. et al. *SAGE Open Med*. 2016 Dec 9;4:2050312116682126. doi: 10.1177/2050312116682126.

166. Skin autofluorescence is associated with arterial stiffness and insulin level in endurance runners and healthy controls - Effects of aging and endurance exercise.

Couppé C. et al. *Exp Gerontol*. 2017 May;91:9-14.

- 167. The association between skin autofluorescence and mean deviation in patients with open-angle glaucoma.**
Himori N, et al. Br J Ophthalmol. 2016 Dec 9.
- 168. Surface Area of Detachment, Proliferative Vitreoretinopathy, and Pulse Pressure, but not AGEs, are Associated With Retinal Redetachment.**
Fokkens BT et al. Invest Ophthalmol Vis Sci. 2016 Dec 1;57(15).
- 169. Skin Autofluorescence Examination as a Diagnostic Tool for Mild Cognitive Impairment in Healthy People.** Igase M. et al. J Alzheimers Dis. 2016 Nov 14. [Epub ahead of print]
- 170. Skin advanced glycation end products in HIV infection are increased and predictive of development of cardiovascular events.**
Sprenger HG. et al. AIDS. 2016 Oct 18.
- 171. The Course of Skin and Serum Biomarkers of Advanced Glycation Endproducts and Its Association with Oxidative Stress, Inflammation, Disease Severity, and Mortality during ICU Admission in Critically Ill Patients: Results from a Prospective Pilot Study.**
Meertens JH et al. PLoS One. 2016 Aug 16;11(8). (FULL TEXT available)
- 172. Relationship between advanced glycation end-product accumulation and low skeletal muscle mass in Japanese men and women.**
Kato M. et al. Geriatr Gerontol Int. 2016 Apr 27. Epub.
- 173. Advanced glycation endproducts and their receptor in different body compartments in COPD.**
Hoonhorst S.J. et al. Respir Res. 2016 Apr 26; 17:46.
- 174. The association between systemic oxidative stress and ocular blood flow in patients with normal-tension glaucoma.**
Himori N. et al. Graefes Arch Clin Exp Ophthalmol. 2016 Feb;254(2):333-41.
- 175. Skin Autofluorescence in Systemic Sclerosis Is Related to the Disease and Vascular Damage: A Cross-Sectional Analytic Study of Comparative Groups.**
Dadoniene J. et al. Dis Markers. 2015;2015:837470. Epub
- 176. Traditional and emerging indicators of cardiovascular risk in chronic obstructive pulmonary disease.**
John M. et al. Chron Respir Dis. 2016 Mar 10.
- 177. A new gender-specific model for skin autofluorescence risk stratification.**
Ahmad M.S. et al. Sci Rep. 2015 May 14;5:10198.
- 178. Achilles tendons in people with type 2 diabetes show mildly compromised structure: an ultrasound tissue characterisation study.**
de Jonge S. et al. Br J Sports Med. 2015 Jan 13 (Epub)
- 179. Does reduction of disease activity improve early markers of cardiovascular disease in newly diagnosed rheumatoid arthritis patients?**
de Groot L. et al. Rheumatology (Oxford). 2015 Jan 12 (Epub)
- 180. Advanced glycation end products in the skin are enhanced in COPD.**
Hoonhorst S.J. et al. Metabolism. 2014 Jun 13. Epub
- 181. Life-long endurance running is associated with reduced glycation and mechanical stress in connective tissue.**
Couppé C. et. al. Age (Dordr). 2014 Aug;36(4):9665.
- 182. Plasma AGEs and skin autofluorescence are increased in COPD.**
Gopal P. et al. Eur Respir J. 2013 May 3. [Epub ahead of print]
- 183. Increased advanced glycation end-products (AGEs) assessed by skin autofluorescence in schizophrenia.** Kouidrat Y. et al. J Psychiatr Res. 2013 Apr 21.

184. **Local differences in skin autofluorescence may not reflect similar differences in oxidative stress exposure.**
Hetteema M. et al. J Rheumatol. 2013 Feb;40(2):206.
185. **Vascular Aspects of Fabry Disease in Relation to Clinical Manifestations and Elevations in Plasma Globotriaosylsphingosine.**
Rombach S.M. et al. Hypertension. 2012 Aug 6. (Epub)
186. **Advanced Glycation Endproducts are increased in RA patients with controlled disease.**
de Groot L. et al. Arthritis Res Ther. 2011 Dec 14;13(6):R205.
187. **Increased skin autofluorescence after colorectal operation reflects surgical stress and postoperative outcome.**
Pol H.W. et al. Am J Surg. 2011 Nov;202(5):583-9.
188. **Skin autofluorescence, as marker of accumulation of advanced glycation endproducts and of cumulative metabolic stress, is not increased in patients with systemic sclerosis.**
Hetteema M.E.. et al. Int J Rheumatol. 2011. Epub
189. **Skin advanced glycation end-product accumulation is negatively associated with calcaneal osteo-sono assessment index among non-diabetic adult Japanese men.**
Momma H. Osteoporos Int. 2011 Sep 8. Epub
190. **Skin autofluorescence is high in patients with cirrhosis - further arguing for the implication of Advanced Glycation End products.**
Maury E. et al. J Hepatol. 2011 May;54(5):1079-80.
191. **Skin advanced glycation end product accumulation and muscle strength among adult men.**
Momma H. et al; Eur J Appl Physiol. 2010 (Epub)
192. **Skin Autofluorescence as Marker of Tissue Advanced Glycation End-Products Accumulation in Formerly Preeclamptic Women.**
Coffeng S.M. et al. Hypertens Pregnancy; 2010, Epub
193. **Accumulation of advanced glycation end (AGEs) products in intensive care patients: an observational, prospective study.**
Greven W. et al. BMC Clinical Pathology; 2010: 10 (4)
194. **Increased accumulation of advanced glycation endproducts in patients with Wegener's granulomatosis.**
Leeuw de K et al. Ann Rheum Dis. 2009; 69(3): 625-U191
195. **Skin autofluorescence is increased in systemic lupus erythematosus but not reflected by plasma levels advanced glycation endproducts**
Nienhuis H. et al: Rheumatology. 2008; 47(10): 1554-1558
196. **Skin autofluorescence is increased in systemic lupus erythematosus but not reflected by plasma levels of advanced glycation endproducts**
Nienhuis H. et al. Rheumatology; 2008; 47(10): 1554-1558
197. **Advanced glycation end products and the absence of premature atherosclerosis in glycogen storage disease Ia**
den Hollander NC. et al. J Inherit Metab Dis. 2007 Nov;30(6):916-23.
198. **Accumulation of advanced glycation endproducts in patients with systemic lupus erythematosus.**
de Leeuw K. et al. Rheumatol 2007;45:1551-1556.
199. **Skin autofluorescence, a marker of advanced glycation end products and oxidative stress, is increased in recently prelamptic women**
Blaauw J. et al. Am J Obstet Gynecol. 2006 Sep;195(3):717-22.
200. **Enhanced skin autofluorescence as a marker for oxidative stress in sepsis, a pilot study.**
Mulder DJ, et al. Eur Soc Intensive Care Medicine 2004

- 201. Use of skin advanced glycation end product levels measured using a simple noninvasive method as a biological marker for the diagnosis of neuropsychiatric diseases** Yamashita et al. *Int J Methods Psychiatr Res.* 2020;29:e1824 <https://doi.org/10.1002/mpr.1824>
- 202. Accumulation rate of advanced glycation end products in recent onset psychosis: A longitudinal study.** Hagen et al. *Psychiatry Research* 291 (2020) 113192 <https://doi.org/10.1016/j.psychres.2020.113192>
- 203. Measures of lung function and their relationship with advanced glycation end-products** Zaigham et al. *2020 ERJ Open Res* 2020; 6: 00356-2019 [<https://doi.org/10.1183/23120541.00356-2019>]

AGE Reader (technical) validation

- 204. Association of advanced glycation end products, evaluated by skin autofluorescence, with lifestyle habits in a general Japanese population.**
Isami et al. *J Int Med Res.* 2018 Jan 1:300060517736914. doi:10.1177/0300060517736914.
- 205. The association between various smoking behaviors, cotinine biomarkers and skin autofluorescence, a marker for advanced glycation end product accumulation.**
van Waateringe RP et al. *PLoS One.* 2017 Jun 20;12(6):e0179330.
- 206. Skin autofluorescence, a non-invasive marker of advanced glycation end products: clinical relevance and limitations.**
Da Moura Semedo C. et al. *Postgrad Med J.* 2017 Jan 31. doi: 10.1136/postgradmedj-2016-134579.
- 207. Lifestyle and clinical determinants of skin autofluorescence in a population-based cohort study.**
van Waateringe R. et al. *Eur J Clin Invest.* 2016 Mar 22. Epub.
- 208. Body mass index, chronological age and hormonal status are better predictors of biological skin age than arm skin autofluorescence in healthy women who have never smoked.**
Randag A.C. et al. *Br J Dermatol.* 2015 Jul 25.
- 209. The skin autofluorescence reflects the posttranslational glycation grade of the matrix protein collagen.** Jacobs K. et al. *Free Radic Biol Med.* 2014 Oct;75 Suppl 1:S34
- 210. GWAS identifies an NAT2 acetylator status tag single nucleotide polymorphism to be a major locus for skin fluorescence.**
Eny K.M. et al. *Diabetologia.* 2014 Aug;57(8):1623-34.
- 211. Reference values of skin autofluorescence as an estimation of tissue accumulation of advanced glycation end products in a general Slovak population.**
Klenovics KS, *Diabet Med.* 2013 Sep 30. doi: 10.1111/dme.12326. (Epub).
- 212. Reference values for the Chinese population of skin autofluorescence as a marker of advanced glycation end products accumulated in tissue.**
Yue X. et al. *Diabet Med.* 2011 Jul;28(7):818-23.
- 213. Dermal factors influencing measurement of skin autofluorescence.**
Noordzij M.J. et al. *Diabetes Technol Ther.* 2011 Feb;13(2):165-70
- 214. Skin color independent assessment of aging using skin autofluorescence**
Koetsier M. et al. *Optics Express,* 2010 ;18(14):14416-29
- 215. Reference Values of Skin Autofluorescence.**
Koetsier M. et al. *Diabetes Technology & Therapeutics* 2010; 12(5):399-403

- 216. Skin autofluorescence for the risk assessment of chronic complications in diabetes: a broad excitation range is sufficient**
Koetsier M. et al: Optics Express. 2009; 17(2): 509-519
- 217. Skin autofluorescence increases postprandially in human subjects**
Stirban A. et al. Diabetes Technology & Therapeutics 2008; 10:200-5
- 218. The Effect of Aggressive Versus Conventional Lipid-lowering Therapy on Markers of Inflammatory and Oxidative Stress.**
Mulder DJ. et al. Cardiovasc Drugs Ther. 2007 Apr;21(2):91-7.
- 219. Skin Autofluorescence, a Novel Marker for Glycation and Oxidative Stress derived Advanced Glycation Endproducts. An Overview of Current Clinical Studies, Evidence and Limitations**
Mulder DJ, et al. Diabetes Technology and Therapeutics 2006; 8:523-535.
- 220. Simple noninvasive measurement of skin autofluorescence**
Meerwaldt R, et al. Ann N Y Acad Sci. 2005;1043:290-298.
- 221. Instrumentation for the measurement of Autofluorescence in the human skin**
Graaff R et al. Proc. of SPIE Vol. 5692 (SPIE, Bellingham, WA, 2005). pp. 111-118.
- 222. Simple non-invasive assessment of advanced glycation endproducts accumulation**
Meerwaldt R et al. Diabetologia 2004; 47:1324-1330
- 223. Accumulation of Maillard reaction products in skin collagen in diabetes and aging.**
Dyer DG et al. J Clin Invest 1993; 91:2463–2469
- 224. Nε-(carboxymethyl)lysine, a product of chemical modification of protein by methylglyoxal, increases with age in human lens proteins.** Ahmed MU et al. Biochem J 1997; 324:565–570
- 225. Prevalence, incidence and mortality of type 2 diabetes mellitus revisited: a prospective population-based study in the Netherlands (ZODIAC-1).** Ubink-Veltmaat LJ et al. Eur J Epidemiol, 2003; 18: 793–800
- 226. Guideline ‘Cardiovascular Risk Management’.** Burgers JS et al. Ned Tijdschr Geneesk 2007;151:1068–1074
- 227. Narrative review: assessment of C-reactive protein in risk prediction for cardiovascular disease.** Lloyd-Jones DM et al. Ann Int Med 2006; 145:35–42
- 228. The Atherosclerosis Risk in Communities Study Investigators (2003) Prediction of coronary heart disease in middle-aged adults with diabetes.** Folsom AR, et al. Diabetes Care 26:2777–2784
- 229. Evaluation of the glycative stress by non-invasive skin AGEs measurement devices.** Morita et al. 2019 Glycative Stress Research 2019; 6 (2): 092-102

AGE Reader in general population

- 230. Skin autofluorescence predicts incident type 2 diabetes, cardiovascular disease and mortality in the general population.** van Waateringe R et al. Diabetologia. 2019 Feb;62(2):269-280 Epub
- 231. Evaluation of skin autofluorescence as a surrogate of advanced glycation end products accumulation in children and adolescents with normal haemoglobin A1c values.** Jankowska et al. 2020 Pediatr Endocrinol Diabetes Metab 2020; 26 (1): 1–9 DOI: <https://doi.org/10.5114/pedm.2020.93251>

AGE Reader in diet and lifestyle

- 1. The association between dietary and skin advanced glycation end products: the Rotterdam Study.** Chen et al. 2020 Am J Clin Nutr 2020;00:1–9

- 2. A physically active lifestyle is related to a lower level of skin autofluorescence in a large chronic disease population (Lifelines cohort)** van de Zande et al. 2020 Journal of Sport and Health Science (2020), doi: <https://doi.org/10.1016/j.jshs.2020.09.007>